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INTRODUCTION
Osteogenesis imperfecta (OI) (MIM# 166200, 166220,
and 259420) is an autosomal dominantly or recessively inher-
ited disorder primarily caused by mutations of type I colla-
gen genes; COL1A1 on chromosome 17 and COL1A2 on
chromosome 7 (1). OI is characterized by osteopenia, multi-
ple bone fractures, dentinogenesis imperfecta, kyphoscolio-
sis, joint hyperlaxity, easily bruised skin, blue sclerae, conduc-
tive hearing loss, inguinal hernia, mitral valve prolapse, and
aortic insufficiency (2). Therefore, a thorough evaluation of
the ear, skin, teeth, cardiovascular, and orthopedic systems
is needed. Bone deformities and recurrent bone fractures are
the major concerns for patients with OI. The disease is clas-
sified into seven types by phenotype and mode of inheritance
(2, 3). In the milder autosomal dominant form (Type I), the
patient shows minimal bone deformities, occasional fractures
before puberty, blue sclerae, dentinogenesis imperfecta, and
normal height. In type II autosomal dominant form, fractures
in utero and perinatal death occur. Type III, an autosomal
dominant or recessive form, causes a high frequency of frac-
tures and severe progressive deformities. In type IV autoso-
mal dominant form, normal sclerae, dentinogenesis imper-
fecta, and less severe deformities are present. Type V OI is
characterized by moderate to severe bone fragility, disloca-
tion of radial head, mineralized interosseous membrane, hyper-
plastic callus, short stature, and white sclerae. Type VI OI is
also a moderate to severe form of the disorder with disordered
mineralization of bone tissue, white sclerae, and scoliosis. Type
VII OI, an autosomal recessive disorder localized to chromo-
some 3p22-24.1, is characterized by bone fragility, rhizomelia,
and coax vara (4).
Recurrent bone fractures and deformities due to general-
ized osteopenia are the major complication of OI. A variety
of agents have been used to increase bone mass and to reduce
the frequency of fractures, such as anabolic steroids, sodium
fluoride, growth hormone, magnesium oxide, and calcitonin.
However, none have reduced the complications of the disease
(4). Bisphosphonates, synthetic analogues of naturally occur-
ring inorganic pyrophosphate, have been commonly used and
considered to be the treatment of choice for moderate to severe
OI in several studies (5-14). In most studies, pamidronate
(3-amino-1-hydroxypropylidene-bisphosphonate) is infused
slowly for 3 consecutive days every 4 months (8-11, 13).
The aim of the present study was to evaluate the short-
term efficacy and safety of monthly infusion of pamidronate
on the frequency of fractures, biochemical effects, and bone
mineral density (BMD) in Korean patients with OI.
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Short-term Efficacy of Monthly Pamidronate Infusion in Patients with
Osteogenesis Imperfecta
We evaluated the efficacy of a monthly infusion of pamidronate on the frequency
of fractures, biochemical effects, and bone mineral density in children with osteo-
genesis imperfecta. Eleven patients from 0.9 to 13.8 yr of age were included in this
study. The patients were administered pamidronate intravenously (30 mg/m
2) over
a 4-hr period monthly for a period ranging from 6 to 37 months. Height and weight
Z-scores did not change significantly. The frequency of fractures was decreased
from 2.3± ±1.01 times per year before treatment to 0.6± ±0.69 times per year during
treatment. There were no long-term changes in biochemical markers during pami-
dronate therapy. The mean bone mineral density of the spine and femur increased
significantly. Monthly intravenous pamidronate therapy decreased frequencies of
fracture and increased bone mineral density without significant adverse events in
Korean patients with osteogenesis imperfecta.
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MATERIALS AND METHODS
Eleven patients showing clinical features of OI such as recur-
rent fractures to minor trauma, blue sclerae, and/or dentino-
genesis imperfecta were included in this uncontrolled pros-
pective study (Table 1). Eight patients were classified as type
IA, two patients as type IB, and one patient as type III. All
patients had generalized osteopenia observable by simple
radiography and dual energy radiography absorptiometry,
and suffered from recurrent fractures 2.3±1.01 times per
year before treatment.
After obtaining informed consent, the patients were ad-
ministered 30 mg/m2 of pamidronate monthly for a period
ranging from 6 to 37 months (20.8±8.11 months) (6).
Pamidronate was diluted in isotonic saline at a concentra-
tion less than 0.1 mg/mL and administered by intravenous
infusion over 4 hr. The patients received 200 mg of elemen-
tal calcium and 0.25  g of 1,25-dihydroxycholecalciferol
(1,25 [OH]2D3) daily for 7 days concurrently. Patients’ age
at the initiation of therapy ranged from 0.9 to 13.8 yr.
The clinical status of height, body weight, growth veloci-
ty, frequency of fractures, and adverse events were evaluated
at each visit for pamidronate infusion. Height for each child
was translated into Z-scores according to the standard height
table for Korean children (15). The fracture incidence was
annualized 2 yr prior to treatment and throughout the treat-
ment period of 6-37 months except in patient 5, who start-
ed treatment at the age of 0.9 yr. Fractures were confirmed
by simple radiographs. Vertebral compression fractures were
excluded in the analysis. The level of ambulation was assessed
according to the modified criteria of Bleck with a 4-point
scale as follows: non walker, score=0; therapeutic walker with
or without the use of crutches, canes, or walker, score=1;
household walker with or without the use of crutches, canes,
or walker, score=2; neighborhood or community walker with
or without the use of crutches, canes, or walker, score=3 (16).
Biochemical markers reflecting bone and mineral metabolism
(serum calcium, phosphate, alkaline phosphatase, osteocalcin,
and parathyroid hormone [PTH]), and BMD were assessed
at 6-month intervals immediately before the application of
pamidronate. Simple radiography of thoracolumbar spine
was taken with BMD for the evaluation of vertebral com-
pression fractures. BMD of the lumbar spine (L2-4) and femur
neck was measured by dual energy radiography absorptiom-
etry (Lunar Corp., Madison, WI, U.S.A.). Age- and sex-ma-
tched BMD Z-scores for Korean children were used for com-
parisons of BMD during treatment (17). The children did not
receive any physiotherapy, occupational therapy or surgical
intervention during the time of the pamidronate therapy.
Statistical analyses were performed with SPSS version 11.0.
Changes before and after treatment were analyzed by a Wilcox-
on signed rank test. Differences of biochemical parameters
at more than two treatment time points were analyzed for
significance using repeated measures ANOVA. p-values less
than 0.05 were considered statistically significant.
RESULTS
Linear growth of patients was not significantly delayed.
Patient 
No.
Age 
at 
initia-
tion of
treat-
ment
(yr)
Duration 
of treat-
ment
(months)
Height 
(Z-score)*
Initial Final
Sex Type
Fracture rate 
per year*
Before
treat-
ment
During
treat-
ment
Spine BMD (g/cm
2)*
Initial Final
Annual 
%
increase
Femur BMD (g/cm
2)*
Initial Final
Annual 
%
increase
1 1A F 7.7 37 0.18 -0.03 0.440 0.722 32.0 0.302 0.622 52.9 1.5 1.0
2 1B M 6.9 26 -0.75 -0.20 0.478 0.667 19.8 0.557 0.725 15.1 1.0 1.0
3 1B F 5.9 26 -1.02 -0.97 0.462 0.765 24.0 0.474 0.726 26.6 3.0 0
4 1A M 12.0 18 -1.22 -1.07 0.554 0.672 10.6 0.568 0.682 10.0 2.0 0
5 1A F 0.9 12 0.12 -0.32 0.342 0.545 59.4 0.496 0.520 2.4 2.0 0
6 1A M 4.4 18 0.02 -0.71 0.458 0.542 19.0 0.479 0.634 39.7 4.0 2.0
7 3 M 2.4 24 -1.37 -1.20 0.290 0.571 48.4 0.372 0.853 64.7 4.0 0
8 1A M 2.7 24 -0.45 -1.20 0.374 0.657 37.8 0.278 0.633 63.8 1.5 0
9 1A M 5.8 18 -1.53 -0.26 0.440 0.598 7.3 0.485 0.656 17.0 1.5 0
10 1A M 13.8 6 -1.42 -0.69 0.626 0.804 14.2 0.659 0.782 9.4 2.5 1.0
11 1A M 2.5 20 -1.76 0.37 0.440 0.545 15.9 0.505 0.660 20.5 2.0 1.0
Mean±SD 5.9± 20.8± -0.8± -0.6± 0.446± 0.644± 26.2± 0.471± 0.681± 29.3± 2.3± 0.6±
8.11 0.71 0.52 0.09 0.06 16.47 0.11  0.09 22.45 1.01  0.69  4.06
Table 1. Clinical characteristics, bone mineral density, and fracture frequency of patients with osteogenesis imperfecta before and
during the pamidronate therapy
*p values represent the significance of difference of results at the two time points (initial vs. final) (p<0.05). 
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During treatment, no significant differences were noted in
height and weight Z-scores although height Z-scores of pa-
tients 1, 5, 6, and 8 were slightly deteriorated. All patients
showed a normal growth velocity although their ages were
variable for the assessment of growth (Table 1). No patients
showed aggravation of long bone deformity and progression
of scoliosis. The ambulation scores were grade 3 before treat-
ment in all patients. There was no change in the level of am-
bulation in patients with OI during treatment. Low-grade
fever developed in 4 patients at the first infusion. No other
side effects were notified during pamidronate therapy.
Baseline levels of serum calcium, phosphorus, alkaline phos-
phatase, PTH, and osteocalcin were normal. There were no
significant differences between age groups. No patients showed
long-term changes in biochemical markers during the treat-
ment period. 
Simple radiography of thoracolumbar spine and both femur
revealed osteopenia and/or compression fractures of spine in
all patients. The frequency of fractures decreased from 2.3±
1.01 times per year before treatment to 0.6±0.69 times per
year during treatment (p<0.05). Pretreatment BMD was at
the low limit of the reference range in all patients. The mean
BMD measured in both the lumbar spine and femur neck
has significantly increased in all patients after treatment (p<
0.05) (Table 1). The average annualized increment in BMD
was 26.2±16.47% in lumbar spine and 29.3±22.45% in
femur neck. The mean BMD Z-scores of spine were signifi-
cantly improved from -2.5±1.75 to 1.5±3.06 (p<0.05), and
those of femur neck also increased from -3.7±0.90 to -1.77
±0.89 (p<0.05). 
DISCUSSION
Infusion of pamidronate for three consecutive days, using
a 4-month interval protocol, is widely used as a therapy for
patients with OI (8-11, 14). Glorieux et al. (9) reported a
safe and favorable outcome when the mean dose was about
6-9 mg/kg per year. Although it is significantly effective,
pamidronate infusions for three consecutive days every four
months take much time and interfere with patients’ daily
life. Two previous studies in Korea also suggested that pami-
dronate therapy in OI using the 3 consecutive days every 2-
4 months protocol increased BMD and decreased fracture
rates (18, 19). Single-day, monthly infusion protocols of pami-
dronate were also shown to be efficacious (6, 7). A simplified
protocol of single-day infusion of pamidronate every 3 months
was tried and turned out to be efficacious and well tolerated
with pediatric patients with osteoporosis. This report sup-
ports the findings of other studies that showed pamidronate
has beneficial effects in patients with OI although a small
cohort population was enrolled in this study. 
Height Z-scores decreased during pamidronate treatment
in some patients. However, changes in height Z-scores were
statistically not significant, and their growth velocity was
normal. Zeitlin et al. (13) reported long-term pamidronate
therapy at least four years led to a significant height gain in
moderately to severely affected OI patients.
No significant adverse events were encountered during
pamidronate therapy except low-grade fever. Self-limited
flu-like symptoms such as decreased appetite, myalgia, irri-
tability, low-grade fever, and decreased energy could be asso-
ciated with pamidronate therapy (8).
Serum calcium, phosphorus, PTH, and vitamin D metabo-
lites are generally normal in patients with OI. Subtle changes
in parameters of bone metabolism during pamidronate ther-
apy, such as serum calcium, phosphorus, PTH, and vitamin
D metabolites, have been reported (11). Serum calcium levels
transiently decreased with a transitory increase in PTH levels
during pamidronate therapy (10, 11). Although serum cal-
cium levels could be decreased, none of the patients showed
symptomatic hypocalcemia (9). The OI patients showed re-
duced levels of serum alkaline phosphatase, osteocalcin, and
urinary excretion of calcium, which are suggestive of slowed
bone turnover (6, 9, 11). The biochemical parameters includ-
ing calcium, phosphorus, alkaline phosphatase, PTH, and
osteocalcin levels did not altered significantly in this study.
Presumably, calcium and vitamin D supplement might con-
tribute to the normalization of the biochemical parameters.
Bisphosphonates are a class of drug that are potent inhibitors
of osteoclastic bone resorption (20, 21), and known to result
in a net effect of increased bone mass and reduced risk of frac-
tures in patients with OI (22, 23). The increase in BMD fol-
lowing therapy results from a reduction in remodeling space
due to both decreased activation of new remodeling cycles
by reducing the population of cells committed to becoming
mature osteoclasts (20). Osteoblasts may have a role in the
inhibition of bone resorption by bisphosphonates. Bisphos-
phonates have been postulated to induce osteoblasts to secrete
an inhibitor of osteoclastic resorption (24). Numerous pre-
liminary studies described that cyclic administration of bis-
phosphonates increased BMD and decreased the frequency
of fractures (5-14). There was no correlation between pheno-
type severity, age at the start of treatment, and treatment res-
ponse (14). In the present study, pamidronate therapy increased
BMD in all patients. Significant improvement in BMD causes
beneficial clinical effects such as significant reduction in frac-
ture frequency, decreased bone pain, and increased mobility
(9, 10). Dual energy radiography absorptiometry provides
the assessment of areal BMD (g/cm2), which is calculated by
dividing the bone mineral content by the projected bone area
of the scanned skeletal region. Since the volume of the scanned
bone is not measured, areal BMD fails to distinguish between
changes in the BMD and bone size in growing children. In-
creased bone mass after pamidronate therapy can be demon-
strated by bone biopsy, showing the influence of the treat-
ment on cortical modeling and enchondral ossification (12).
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during and after pamidronate therapy. The sclerotic lines
observed in the metaphyses during treatment indicated no
significant functional impairment (25).
In summary, monthly pamidronate treatment was safe and
effective in Korean patients with OI. Although the period
of treatment and the age of the subjects varied considerably
making it difficult to draw a definitive conciusion, monthly
intravenous pamidronate therapy in patients with OI improved
clinical symptoms, decreased the frequency of fractures, and
increased BMD without significant adverse events. The chro-
nic effects of pamidronate on bone metabolism in OI patients
are not yet known. Therefore, randomized, well-controlled
studies are needed for the evaluation of the efficacy, adverse
effects, appropriate treatment interval, optimal duration, and
dosage of pamidronate. 
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